NYSE · LLY
Eli Lilly and Company
$1,423.64+$49.94 (+3.64%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 1.8% below the high.
Loading market information…
HKSE · 1521.HK · HKD
Stock price, earnings
Quote as of Oct 21, 2026, 08:08 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Frontage Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Frontage Holdings Corporation’s next earnings report is currently expected on Mar 29, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Frontage Holdings Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Frontage Holdings Corporation functions as a contract research organization (CRO), delivering a broad spectrum of laboratory and associated services to the pharmaceutical, biotechnology, and agrochemical sectors, alongside performing vital bioequivalence assessments. The company's diverse service portfolio includes specialized laboratory testing, covering method development, validation, sample analysis, and central laboratory operations. They also provide Chemistry, Manufacturing, and Control (CMC) support, assisting with drug product development and analysis, as well as the provision of clinical trial materials. Furthermore, Frontage offers Drug Metabolism and Pharmacokinetics (DMPK) services, encompassing study design, execution, and data interpretation for tasks such as structural optimization in early discovery, pharmacokinetic studies in rodents, and non-GLP bioanalytical analyses. Their capabilities extend to comprehensive safety and toxicology evaluations through both in vitro and in vivo studies, as well as robust bioequivalence (BE) services from design through reporting. Additionally, the company undertakes chemistry services, including contract research and custom synthesis, and provides an array of clinical services like early-stage clinical trials, BE/BA studies, biometrics, and data management. Frontage maintains a global operational footprint, with a presence in the United States, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. Established in 2018 and headquartered in Exton, Pennsylvania, Frontage Holdings Corporation is a subsidiary of Hongkong Tigermed Co., Limited.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:34 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 | Oct 27, 2023 | HK$0.04 | HK$1.01B-5.45% vs estimate |
|---|
| Q4 2022 | Mar 28, 2023 | HK$0.07-15.0% vs estimate | HK$1.03B+0.28% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,423.64+$49.94 (+3.64%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 1.8% below the high.
$275.46+$0.26 (+0.09%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.32% below the high.
$295.16+$4.37 (+1.5%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.2% below the high.
$150.25+$3.92 (+2.68%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.25% below the high.
$408.58-$2.33 (-0.57%)
UnitedHealth Group Incorporated’s quoted price sits in the upper half of its reported 52-week range, 11.49% below the high.
HK$44.48-HK$0.58 (-1.29%)
WuXi Biologics (Cayman) Inc.’s quoted price sits in the upper half of its reported 52-week range, 23.31% below the high.
HK$19.10-HK$0.31 (-1.6%)
Medtide Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.28% below the high.
HK$1.25-HK$0.03 (-1.96%)
Viva Biotech Holdings’s quoted price sits in the lower half of its reported 52-week range, 56.29% below the high.
